| abstract |
In certain aspects, the present invention provides methods and compositions for determining whether a cancer cells is likely to respond to treatment with a Her2-acting agent. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis. |